Diagenta

Diagenta is a private healthcare technology and clinical trial services company that combines at-home care delivery, decentralized clinical trial operations, point-of-care diagnostics, and bioanalytical laboratory services. The company markets the DiaBag mobile diagnostic platform and the DiaLogic software platform to support home-based diagnosis, treatment, triage, remote monitoring, and hybrid care workflows. Diagenta also operates clinical trial and PK/PD laboratory capabilities, with a stated focus on early-phase and decentralized studies, particularly through its Australia-based operations. Its service offering spans patient care, mobile diagnostics, telehealth-enabled workflows, and pharmacology/bioanalysis support for clinical development. Publicly visible pipeline information appears limited, but the company is currently promoting enrollment for a Phase IIa COVID-19 study involving third-party investigational drug 83-0060 rather than clearly disclosing an internal therapeutic pipeline.